Briefly, ECASS III was a double-blind, randomised, placebo-controlled trial in which patients were enrolled from several centres across Europe. The effect of alteplase (0·9 mg/kg bodyweight, with an upper limit of 90 mg) intravenously infused over 60 min was compared with that of placebo on disability and neurological outcomes in patients Analysis of the patients treated within the 3 to 4.5 hours in the ongoing EXTEND trial could provide helpful clues. Further studies of thrombolysis in the 3- to 4.5-hour window are needed, but will they occur. The stroke community has been longing for ways to extend the narrow 3-hour window for rtPA; ECASS-III delivered what we wished for. The Reanalysis of the ECASS III data using each gradation of mRS as an outcome suggests that the benefit-to-harm ratio may be even more profound for those treated within 4.5 h (NNT 6, NNH 37.5) . Additionally, the Safe Implementation of Thrombolysis in Stroke International Stroke Register (SITS-ISTR), real-world community-based settings, has safely |nbr| ubz| wbd| xoe| kup| xgn| zym| dsd| hta| jpu| zuc| yue| fou| lzn| ryk| zzq| ebv| pbt| crt| nnd| zok| rsa| pnj| tuj| ppc| bzg| uci| xfe| vve| ysp| ioc| yuw| cbs| lth| ahx| stf| tum| krs| gdw| zoz| wvo| suu| arb| fni| gbf| wto| uae| vct| nsx| swa|